✦ LIBER ✦

Drug targets: single-cell transcriptomics hastens unbiased discovery

✍ Scribed by Tamas Bartfai; Peter T. Buckley; James Eberwine

Book ID: 116919079
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 380 KB
Volume: 33
Category: Article
ISSN: 0165-6147
DOI: 10.1016/j.tips.2011.09.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single-cell transcriptomics for drug tar

Single-cell transcriptomics for drug target discovery

✍ Spaethling, Jennifer M; Eberwine, James H 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 531 KB

[RSC Drug Discovery] Neglected Diseases

[RSC Drug Discovery] Neglected Diseases and Drug Discovery || Chapter 4. Human Targets Repositioning and Cell-based Approaches for Antimalarial Discovery

✍ Palmer, Mike; Wells, Timothy N.C. 📂 Article 📅 2011 🏛 Royal Society of Chemistry ⚖ 592 KB

Cancer Drug Design and Discovery || A Ne

Cancer Drug Design and Discovery || A New Generation of Cell-Targeted Drugs for Cancer Treatment

✍ Arimondo, Paola B. 📂 Article 📅 2014 🏛 Elsevier ⚖ 750 KB

Single-bead, Single-molecule, Single-cel

Single-bead, Single-molecule, Single-cell Fluorescence : Technologies for Drug Screening and Target Validation

✍ Martin Hintersteiner; Manfred Auer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

[Methods and Principles in Medicinal Che

[Methods and Principles in Medicinal Chemistry] Epigenetic Targets in Drug Discovery Volume 42 || Epigenetic Targets in Drug Discovery: CellâBased Assays for HDAC Inhibitor Hit Validation

✍ Sippl, Wolfgang; Jung, Manfred 📂 Article 📅 2009 🏛 Wiley ⚖ 210 KB 👁 2 views

Targeting cell signaling pathways for dr

Targeting cell signaling pathways for drug discovery: An old lock needs a new key

✍ Bharat B. Aggarwal; Gautam Sethi; Veera Baladandayuthapani; Sunil Krishnan; Shis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

## Abstract In this age of targeted therapy, the failure of most current drug‐discovery efforts to yield safe, effective, and inexpensive drugs has generated widespread concern. Successful drug development has been stymied by a general focus on target selection rather than clinical safety and effic